DBPR22998:A Potent QPCTL (IsoQC) Inhibitor Targeting CD47-SIRP⍺ Axis for Cancer Immunotherapy
The invention describes a potent, orally bioavailable small molecule isoQC inhibitor targeting the CD47-SIRP⍺ immune checkpoint signal. DBPR22998 effectively inhibits isoQC enzyme activity, thereby reducing the binding of CD47 and SIRPα on the surface of tumor cells and the "don＇t eat me" signal. DBPR22998 is best used in combination with monoclonal antibody-targeted drugs or immune checkpoint antibodies to promote antibody-dependent cell phagocytosis and enhance tumor elimination.
Novel Small Molecule AXL and MERTK Dual Tyrosine Kinase Inhibitor as A nti-Tumor and Immunomodulatory Agent
A Site-Specific B7-H3 Targeting Antibody-Drug Conjugate for Cancer Therapy
DBPR22998:A Potent QPCTL (IsoQC) Inhibitor Targeting CD47-SIRP⍺ Axis for Cancer Immunotherapy
Development of novel cannabinoid CB1receptor antagonists with high oral absorption and no central adverse effects for the treatment of cardiovascular diseases
Technology maturity：Prototype
Exhibiting purpose：Display of scientific results
Trading preferences：Negotiate by self
Coming soon!